Gilead reports Q4 earnings on Feb. 11. Analysts expect $1.70 EPS. The LEO Pharma deal could reduce 2025 EPS by up to $0.17.

New, innovative therapies must be added to the existing arsenal of treatments for adult female acne, according to a ...

Incyte’s ruxolitinib franchise, made up of blockbuster JAK inhibitor Jakafi and its topical counterpart Opzelura, have been ...

DEBRA Research and LEO Pharma enter strategic partnership to advance treatments for rare skin diseases: Munich, Germany Thursday, February 6, 2025, 10:00 Hrs [IST] DEBRA Research ...

Biotech stocks are revolutionizing healthcare with breakthrough innovations, leading the charge in precision therapies and ...

Operator Good afternoon, everyone, and welcome to Gilead's fourth quarter and full year 2024 earnings conference call. My ...

The Board of Directors of Aqilion AB (publ) ("Aqilion" or the "Company") has on 11 February 2025, based on the authorization granted by the Annual General Meeting on 10 June 2024, resolved to carry ...

Cindy Perettie; Executive Vice President of Kite; Gilead Sciences Inc. Geoffrey Meacham; Analyst; Citi. Terence Flynn; Analyst; Morgan Stanley. Timothy Anderson; Analyst; BofA Glo ...

January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

LEO Pharma and non-profit organisation DEBRA Research have announced a collaboration aimed at accelerating the development of treatments for epidermolysis bullosa (EB). The non-exclusive strategic ...

The phase 3 DELTA TEEN trial evaluating Anzupgo 20 mg/g cream for the treatment of chronic hand eczema in adolescents has ...